Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 1—January 2017

Research

Estimated Incidence of Antimicrobial Drug–Resistant Nontyphoidal Salmonella Infections, United States, 2004–2012

Felicita MedallaComments to Author , Weidong Gu, Barbara E. Mahon, Michael Judd, Jason P. Folster, Patricia M. Griffin, and Robert M. Hoekstra
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 1

Number of nontyphoidal Salmonella isolates with clinically important resistance, by resistance category, United States, 2004–2012. Three mutually exclusive categories were defined. Isolates in each category may have resistance to other agents: 99% of the 599 Cef/Amp isolates, 43% of the 467 Cipro isolates, and 89% of the 1,254 Amp-only isolates were resistant to >1 antimicrobial class other than cephems, quinolones, or penicillins. Amp-only, resistant to ampicillin but susceptible to ceftriax

Figure 1. Number of nontyphoidal Salmonella isolates with clinically important resistance, by resistance category, United States, 2004–2012. Three mutually exclusive categories were defined. Isolates in each category may have resistance to other agents: 99% of the 599 Cef/Amp isolates, 43% of the 467 Cipro isolates, and 89% of the 1,254 Amp-only isolates were resistant to >1 antimicrobial class other than cephems, quinolones, or penicillins. Amp-only, resistant to ampicillin but susceptible to ceftriaxone and ciprofloxacin; Cef/Amp, resistant to ceftriaxone (MIC >4 μg/mL) and ampicillin (MIC >32 μg/mL); Cipro, nonsusceptible to ciprofloxacin (MIC >0.12 μg /mL) but susceptible to ceftriaxone; NTS, nontyphoidal Salmonella.

Main Article

TOP